Casebia Therapeutics
About Casebia Therapeutics
Drawing on CRISPR/Cas9 technology and expertise from CRISPR Therapeutics and the distinctive disease know-how and protein engineering capabilities of Bayer, we are working to redefine what’s possible for patients with a wide range of inherited diseases. Some of the areas we are working in are hemophilia, ophthalmic disorders and immunodeficiencies.
We are driven above all by the unprecedented opportunity to transform the lives of patients and families affected by a wide array of genetic diseases. Learn about how we are harnessing the power of gene editing to create fundamental breakthroughs for patients and families by visiting www.casebia.com.
Our vision is "We aspire to cure genetic diseases and change the lives of every patient and family we treat." Our values include Excellence, Collaboration and Urgency, Adaptability, Integrity and Dedication.
EDITING THE GENOME TO CURE GENETIC DISEASE
Created in 2016, Casebia is a joint venture between CRISPR Therapeutics and Bayer. Casebia combines CRISPR/Cas9 expertise and technology from CRISPR Therapeutics with access to deep disease-state knowledge and protein engineering capabilities from Bayer. Our aim: to transform the lives of patients and families affected by genetic disease.
We are located at 610 Main Street in Cambridge, MA 02139 and also 455 Mission Bay Boulevard South in San Francisco, California 94158.
17 articles about Casebia Therapeutics
-
CRISPR Therapeutics and Bayer Announce an Update on Casebia Therapeutics
10/21/2019
Upon closing of the transaction, Casebia Therapeutics would focus on the development of its lead programs in hemophilia, ophthalmology and autoimmune diseases, with Bayer having opt-in rights for two products at IND submission.
-
Casebia Highlights Novel Research in Gene Editing Therapeutics for Hemophilia A
7/8/2019
Early-stage animal model data presented during the ISTH 2019 Congress demonstrates ability to edit hepatocytes and accurately tune production of Factor VIII
-
Casebia Announces Appointment of New SVP, Head of Technical Operations
6/4/2019
Stephen Kennedy to join Casebia’s growing leadership team to lead the company’s development and manufacturing department
-
Casebia Advances Genetic Engineering with New Tools and Techniques
4/24/2019
Ten abstracts that will be presented at ASGCT 2019 showcase the company’s innovative approach as it advances a broad array of gene editing programs
-
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
-
BioSpace Movers and Shakers Nov. 5
11/5/2018
Biopharma companies make key appointments to fill leadership positions. Let's take a look! -
Casebia Therapeutics Expands Leadership Team with Addition of Dr. Adel Nada as Chief Medical Officer
10/31/2018
Dr. Nada joins Casebia from Intellia Therapeutics to lead and advance the company’s pre-clinical and clinical development activities.
-
Casebia Therapeutics Appoints Amy Jennings to Head Its Regulatory Affairs
5/30/2018
Casebia Therapeutics, a biopharmaceutical company dedicated to the creation of life-transforming therapeutics through gene-editing technology, has appointed Amy Jennings, Ph.D., as its head of Regulatory Affairs.
-
CRISPR Therapeutics and Casebia Collaborate With CureVac on mRNA for Gene-Editing Programs
11/13/2017
CureVac’s mRNA technology accessed to express Cas9 for in vivo liver-targeted therapies .
-
Casebia Therapeutics Announces License And Collaboration Agreements With Seattle Children's Research Institute
9/27/2017
-
Casebia Therapeutics Strengthens Leadership Team With Two Key Appointments
9/8/2017
-
Casebia Therapeutics Names Robin A. Walker As Vice President, Head Of Legal
6/28/2017
-
Casebia Therapeutics Expands Leadership Team
5/11/2017
-
CRISPR And Casebia Therapeutics Announce Exclusive Development And Option Agreement With StrideBio
4/17/2017
-
CRISPR And Casebia Therapeutics Announce Commercial License Agreement With MaxCyte, Inc.
3/14/2017
-
Former Sanofi Genzyme Exec to Helm CRISPR/Cas9 Developer Casebia Therapeutics
11/1/2016
-
Bayer and CRISPR Form 80 Employee Joint Venture Named Casebia Therapeutics in Boston Area
8/22/2016